The post Ripple v. SEC end of 2025 case update  appeared on BitcoinEthereumNews.com. The long-running legal battle between blockchain firm Ripple and the SecuritiesThe post Ripple v. SEC end of 2025 case update  appeared on BitcoinEthereumNews.com. The long-running legal battle between blockchain firm Ripple and the Securities

Ripple v. SEC end of 2025 case update

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

The long-running legal battle between blockchain firm Ripple and the Securities Exchange Commission (SEC) reached its definitive conclusion in 2025, ending one of the most consequential regulatory cases in cryptocurrency history.

After nearly five years of litigation, appeals, and procedural delays, both parties exited the case with the core elements of Judge Analisa Torres’s earlier ruling intact, delivering long-awaited clarity on XRP’s status in the U.S. market.

At the start of 2025, the case remained technically unresolved. Although Ripple had secured a partial victory in 2023, when the court ruled that XRP sales on public exchanges did not constitute securities transactions, both Ripple and the SEC were still pursuing appeals.

Decisive moment for Ripple v. SEC

The first meaningful shift came mid-year, when Ripple dropped its cross-appeal, signaling a clear intent to bring the dispute to a close. The move was widely interpreted as confidence that the existing ruling sufficiently protected Ripple’s operations and XRP’s market position.

The decisive moment followed in the second half of 2025, when the SEC formally withdrew its appeal, and both sides dismissed all remaining claims.

Under the final settlement framework, Ripple agreed to pay a $125 million civil penalty tied to past institutional sales, far below the amount initially sought by the regulator.

Crucially, the court’s finding that XRP is not a security when traded on secondary markets remained unchanged, and no new restrictions were imposed on retail trading.

The case’s conclusion coincided with a shift in the U.S. political landscape. A more crypto-friendly administration entered the White House in early 2025, marking a broader move away from regulation through enforcement.

The new Donald Trump administration emphasized regulatory clarity, innovation, and global competitiveness in digital assets, prompting federal agencies to reassess their approach.

Against this backdrop, the SEC scaled back several high-profile crypto cases, making the continued pursuit of the Ripple appeal increasingly misaligned with the administration’s policy direction.

XRP price reaction

Markets reacted swiftly once the case was formally closed. XRP rallied into the low-to-mid $3 range, reflecting relief that the long-standing regulatory overhang had been lifted. However, the move lacked sustained follow-through, as much of the outcome had already been priced in, and broader market conditions limited upside.

As 2025 progressed, XRP settled into a more range-bound phase, trading just above $2, weighed down by broader market sentiment. As of press time, the token was trading at $1.93, up more than 3% over the past 24 hours, though still down over 5% on the weekly timeframe.

Despite the legal clarity opening the door for institutional capital and potential approval of spot XRP exchange-traded funds (ETFs), the asset has shown limited price movement, suggesting investors remain cautious amid wider market uncertainty.

Featured image via Shutterstock

Source: https://finbold.com/ripple-v-sec-end-of-2025-case-update/

Market Opportunity
Belong Logo
Belong Price(LONG)
$0.001947
$0.001947$0.001947
-0.51%
USD
Belong (LONG) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09